Tuspetinib - Aptose Biosciences
Alternative Names: C0WUS7XXE9; HM-43239; TUSLatest Information Update: 19 May 2025
At a glance
- Originator Hanmi Pharmaceutical
- Developer Aptose Biosciences
- Class Alkaloids; Antineoplastics; Benzene derivatives; Camptothecins; Chlorinated hydrocarbons; Cyclopropanes; Indoles; Piperazines; Pyrimidines; Small molecules; Toluenes
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; MAP kinase kinase kinase 7 inhibitors; Proto-oncogene protein c-kit inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 08 May 2025 Updated efficacy and safety data from a phase I/II trial in Acute myeloid leukaemia released by Aptose Biosciences
- 08 May 2025 Aptose Biosciences plans a pivotal phase II/III trial for Acute myeloid leukemia
- 20 Feb 2025 Interim adverse events, efficacy and pharmacokinetics data from the phase-I/II Tuscany trial in Acute myeloid leukaemia released by Aptose Biosciences